Study limitation reported by the research below: “Treatment selection bias is likely: patients assigned shorter venetoclax durations (7–14 days) had substantially higher early mortality rates, suggesting they were clinically frailer or had higher-risk disease at baseline, which could confound comparisons across duration groups.”